Rapport Therapeutics is a scientific partnership startup focused on the development of precision neuromedicines. The company is led by Steve, a seasoned professional with over 40 years of R&D leadership experience. He has co-founded and led multiple companies in the biotechnology and pharmaceutical industry, including Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics.

Rapport operates in the healthcare and pharmaceutical market, specifically targeting neurological disorders. The company's primary clients are patients suffering from drug-resistant epilepsies and mood disorders. Rapport's business model revolves around the discovery and development of novel drugs that act only on disease-relevant areas in the brain, thereby reducing symptoms and side effects of treatment regimens.

Rapport's discovery platform is designed to identify drugs with selectivity to enhance patient benefit. This is achieved by embedding region-specific RAPs (Receptor Associated Proteins) into their drug discovery and development processes. RAPs function in discrete and specific cell types or brain regions, and by targeting these areas, Rapport aims to create more effective treatments for neurological disorders.

The company generates revenue through the development and sale of these precision neuromedicines. Additionally, they may also earn income from conducting clinical trials and providing related services.

Keywords: Precision Neuromedicines, Neurological Disorders, Drug Discovery, Drug Development, RAPs, Receptor Associated Proteins, Drug-Resistant Epilepsies, Mood Disorders, Clinical Trials, Biotechnology.